Similar articles

• Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study.

  Krook AL, Stokka D, Heger B, Nygaard E. Krook AL, et al. Eur Addict Res. 2007;13(4):216-21. doi: 10.1159/000104884. Eur Addict Res. 2007. PMID: 17851243 Clinical Trial.
• Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs.

  Millson P, Challacombe L, Villeneuve PJ, Strike CJ, Fischer B, Myers T, Shore R, Hopkins S. Millson P, et al. Eur Addict Res. 2006;12(2):74-82. doi: 10.1159/000090426. Eur Addict Res. 2006. PMID: 16543742
• Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use.

  Verrando R, Robaeys G, Matheï C, Buntinx F. Verrando R, et al. Acta Gastroenterol Belg. 2005 Jan-Mar;68(1):81-5. Acta Gastroenterol Belg. 2005. PMID: 15832591 Review.
• Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.

  Watson B, Conigrave KM, Wallace C, Whitfield JB, Wurst F, Haber PS. Watson B, et al. Drug Alcohol Rev. 2007 May;26(3):231-9. doi: 10.1080/09595230701247681. Drug Alcohol Rev. 2007. PMID: 17454012
• [Hepatitis C and drug use: epidemiology, screening, natural history and treatment].

  Lucidarme D. Lucidarme D. Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B112-20. Gastroenterol Clin Biol. 2002. PMID: 12180278 Review. French. No abstract available.